Cumberland announces availability of Vibativo 4-Vial Starter Pak through Vizient

Cumberland (CPIX) Pharmaceuticals announced the availability of the Vibativo, or telavancin, 4-Vial Starter Pak through a new contract with Vizient, the nation’s largest provider-driven healthcare performance improvement company. Vizient serves more than 65% of the nation’s acute care providers, including 97% of academic medical centers and 35% of the non-acute market. Through this agreement, Vizient members now have increased access to Vibativ’s new 4-vial configuration, which supports flexible treatment initiation in both inpatient and outpatient settings for this potentially life-saving therapy. Vibativ is an FDA-approved injectable antibiotic indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia as well as complicated skin and skin structure infections caused by Gram-positive pathogens, including MRSA.